Jeena Sikho Lifecare Limited has informed the Exchange regarding Investor Presentation for the upcoming earning concall on Financial Results for half year ended and Financial Year ended March 31, 2025.
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jeena Sikho Lifecare filed its FY25 investor presentation ahead of the earnings call scheduled for May 20, 2025. The company reported FY25 revenue of ₹469 Cr, up 45% year-on-year, with PAT rising 31% to ₹91 Cr. IPD patient volumes jumped 87% to 24,578, and operational bed capacity reached 1,600 with a record 1,218 additional beds in the pipeline. The products division grew 16% to ₹215 Cr while the services division contributed ₹254 Cr. Management flagged slight compression in EBITDA margins (27% vs 29% in FY24) due to higher procurement costs and upfront employee expenses tied to rapid expansion, but expects margins to normalize as new hospitals ramp up. The company also announced its first international foray via a 100% subsidiary in UAE and plans to roll out 15 new products.
Strong top-line and bottom-line growth, robust ROCE of 63%, and debt-free balance sheet support the bull case, but the disclosed margin compression and rising operating costs from aggressive expansion may weigh on near-term profitability. Investors will be watching the earnings call for clarity on margin recovery timelines and mainboard listing plans.